Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges

Published:2017-11-16 Issue:29 Volume:23 Page:
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Ling Yuan¹,Zhang Zikang¹,Zhang Hua¹,Huang Zunnan¹

Affiliation:

1. Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan, China

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts;Blood Cancer Discovery;2024-05-01

2. Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue;Pharmaceutics;2022-08-06

3. GC / MS characterization and computational kinome‐wide screening of pomegranate fruit extract identifies key phytochemicals interacting to CDK kinases implicated in acute myeloid leukemia cells;Journal of Food Biochemistry;2022-04-22

4. FAM122A promotes acute myeloid leukemia cell growth through inhibiting PP2A activity and sustaining MYC expression;Haematologica;2020-04-30

5. GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo;Translational Oncology;2020-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP